Arbor Biotechnologies Stock
HealthTechLooking to sell Arbor Biotechnologies stock or options?
Arbor Biotechnologies develops genomic tools aimed at enhancing human health and promoting sustainability. The company's technology leverages AI and machine learning to compile genomic sequence data, optimizing future cycles of treatments for genetic diseases previously deemed incurable. This enables drug developers to perform whole-gene replacements and accurately correct mutations, facilitating treatment for all patients with genetic disorders.
ARCH Venture Partners, TCG Crossover Management, Ally Bridge Group, Illumina Ventures, GreatPoint Ventures, Deep Track Capital, ArrowMark Partners, T. Rowe Price Group, Tao Capital Partners, MIT Startup Exchange, Piper Sandler, Janus Henderson Investors, Ono Venture Investment, Woodline Partners, Temasek Holdings, S32, Surveyor Capital, Faridan, Vertex Pharmaceuticals, Ridgeback Capital, Logos Capital, Alexandria Venture Investments.
Our available services for this company
Management Team
Board Members
Arbor Biotechnologies’s stock FAQs
Arbor Biotechnologies is currently a private company. This means that the company is not listed on any public exchange and so there is no public market for its stock. However, there may still be ways to monetize Arbor Biotechnologies stock. Depending on Arbor Biotechnologies’s policies, you may be able to: (1) find a private buyer in the secondary market to purchase your stock, (2) borrow against your stock, or (3) exchange Arbor Biotechnologies stock into the Collective Exchange Fund for a limited partnership interest and then borrow non-recourse against your interest to generate immediate cash. This last alternative can be much quicker and net you more after-tax cash than your other options. An exchange into our fund also reduces your risk by diversifying your holdings out of an over-concentrated position.
Collective Liquidity can provide liquidity to shareholders of Arbor Biotechnologies stock in two ways. First, Arbor Biotechnologies employees can exchange shares into the Collective Exchange Fund and then borrow non-recourse to generate immediate cash. This can net you more after-tax cash than a stock sale. It also reduces your risk by diversifying your holdings out of an over-concentrated position. In some cases, Collective may also be able to purchase your Arbor Biotechnologies stock. Note that all transactions in Arbor Biotechnologies shares are subject to the company’s policies regarding secondary transactions. Schedule a call with a Collective Liquidity representative to learn more about your private market liquidity alternatives.
Arbor Biotechnologies stock is not listed on any public exchange and so there is no public market for its shares. Therefore, there is no single, centralized price for Arbor Biotechnologies stock. Typically, shares of private companies like Arbor Biotechnologies are set with buyers in one off negotiations. Collective Liquidity, however, uses a proprietary algorithm to determine its bids so we almost always have an immediately actionable price for you.
On Sep 2024, Arbor Biotechnologies is reported to have closed an equity financing in which the investors valued the company at $263M. This valuation is typically calculated by multiplying the per share price of the preferred stock sold in the financing by the number of Arbor Biotechnologies shares outstanding assuming the conversion of all stock options, warrants, etc.
Tickers are used to identify company’s shares on public markets like the NYSE or Nasdaq. Because Arbor Biotechnologies is not currently publicly traded, it does not have a ticker symbol.
Arbor Biotechnologies has not yet conducted an initial public offering (“IPO”) and so remains a private company. Though Arbor Biotechnologies is a well-known, successful company, there can be no assurance that it will ever go public or be sold. Because of the risk this imposes on Arbor Biotechnologies shareholders, many investors elect to gain liquidity for at least some of their shares before the IPO. Schedule a call with a Collective Liquidity representative to discuss your private market liquidity alternatives.
